iRhythm Technologies provides diagnostic monitoring solutions that facilitate the early diagnosis and treatment of cardiac arrhythmia.
iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 21, 2020 | Post-IPO Secondary | $220M | — | — | — | Detail |
| Sep 11, 2019 | Post-IPO Equity | $115M | — | — | — | Detail |
| Oct 20, 2016 | IPO | $107M | — | — | — | Detail |
| May 22, 2014 | Series E | $27.34M | 2 |
Novo Holdings
|
— | Detail |
| Apr 10, 2013 | Series D | $16M | 5 |
Norwest Venture Partners
|
— | Detail |
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 10, 2019
Parsley Health
|
Series B | $26M | Health Care | — |
|
Apr 21, 2016
Sibly
|
Seed | — | Health Care | — |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Novo Holdings
|
Yes | Series E |
California HealthCare Foundation
|
Yes | Series Unknown |
Norwest Venture Partners
|
— | Series E |
|
|
— | Series D |
New Leaf Venture Partners
|
— | Series D |
Stanford University
|
— | Series D |
Synergy Life Science Partner
|
— | Series D |
Mohr Davidow Ventures
|
— | Private Equity(PE) |
St. Jude Medical
|
— | Series Unknown |
TBJ Investments
|
— | Series A |